Hatch-Waxman Integrity Act of 2019

Bill: 116-hr-990
Sponsor: full_name: Rep. Flores, Bill [R-TX-17]
Introduced: 2019-02-06
Policy area: Health
Subjects: Administrative remedies

Drug safety, medical device, and laboratory regulation

Fraud offenses and financial crimes

Intellectual property

Licensing and registrations

Prescription drugs

Securities
Latest action: action_date: 2019-02-06
text: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summaries:
action_date: 2019-02-06
action_desc: Introduced in House
text: <p><b>Hatch-Waxman Integrity Act of 2019</b></p> <p>This bill establishes certain limits on the filing of patent validity challenges with the Patent Trial and Appeal Board, particularly with respect to inter partes review.<br /></p>

tv_txt: I 116th CONGRESS 1st Session H. R. 990 IN THE HOUSE OF REPRESENTATIVES February 6, 2019 Mr. Flores introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Financial Services , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation, and for other purposes.

1. Short title This Act may be cited as the Hatch-Waxman Integrity Act of 2019 . 2. Preventing the inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and with respect to drug innovation (a) Brand name drugs Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(b)(2) ) is amended— (1) in subparagraph (A)(iv), by striking and at the end; (2) in subparagraph (B), by striking the period at the end and inserting ; and ; and (3) by adding at the end the following: (C) in each certification required under subparagraph (A) with respect to a patent, a certification that— (i) neither the applicant nor any party in privity with, related to, or cooperating with the applicant has filed, or will file, a petition to institute inter partes review or post-grant review of that patent under chapter 31 or 32, respectively, of title 35, United States Code; and (ii) in making the certification required under subparagraph (A), the applicant is not relying in whole or in part on any decision issued by the Patent Trial and Appeal Board in an inter partes review or post-grant review under chapter 31 or 32, respectively, of title 35, United States Code. . (b) Generic drugs Section 505(j)(2)(A) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355(j)(2)(A) ) is amended— (1) in clause (vii)(IV), by striking and at the end; (2) in clause (viii), by striking the period at the end and inserting ; and ; (3) by inserting after clause (viii), as amended by paragraph (2), the following: (ix) in each certification required under clause (vii) with respect to a patent, a certification that— (I) neither the applicant nor any party in privity with, related to, or cooperating with the applicant has filed, or will file, a petition to institute inter partes review or post-grant review of that patent under chapter 31 or 32, respectively, of title 35, United States Code; and (II) in making the certification required under clause (vii), the applicant is not relying in whole or in part on any decision issued by the Patent Trial and Appeal Board in an inter partes review or post-grant review under chapter 31 or 32, respectively, of title 35, United States Code. ; and (4) in the flush text following clause (ix), as added by paragraph (3), by striking (viii) and inserting (ix) . (c) Biosimilar drugs; evaluation by the Secretary Section 351(k) of the Public Health Service Act ( 42 U.S.C. 262(k) ) is amended— (1) in paragraph (2)(A)(iii)— (A) by redesignating subclauses (I) and (II) as items (aa) and (bb), respectively, and adjusting the margins accordingly; (B) in the matter preceding item (aa), as so redesignated, by striking An application and inserting the following: (I) In general An application ; (C) in subclause (I), as so designated— (i) in item (aa), as so redesignated, by striking and at the end; (ii) in item (bb), as so redesignated, by striking the period at the end and inserting ; and ; and (iii) by adding at the end the following: (cc) shall, with respect to a patent described in subclause (II), include a certification that neither the applicant nor any party in privity with, related to, or cooperating with the applicant has filed, or will file, a petition to institute inter partes review or post-grant review of the patent under chapter 31 or 32, respectively, of title 35, United States Code. ; and (D) by adding at the end the following: (II) Patent described A patent is described in this subclause if— (aa) the patent covers the reference product or a method for using the reference product; and (bb) (AA) the reference product described in item (aa) is marked under section 287(a) of title 35, United States Code; or (BB) there is otherwise public notice regarding the applicability of the reference product described in item (aa). ; and (2) in paragraph (3)— (A) in subparagraph (A)(ii), by striking and at the end; (B) in subparagraph (B), by striking the period at the end and inserting ; and ; and (C) by adding at the end the following: (C) the Secretary determines that the application fully complies with the requirements under paragraph (2)(A)(iii). . 3. Preventing the manipulative and deceptive use of inter partes review Section 10(b) of the Securities Exchange Act of 1934 ( 15 U.S.C. 78j(b) ) is amended— (1) by inserting (1) after (b) ; and (2) by adding at the end the following: (2) For purposes of paragraph (1), a person shall be considered to be using a manipulative or deceptive device if— (A) the person, or an affiliate of the person, files a petition to institute an inter partes review under chapter 31 of title 35, United States Code, with respect to a patent; and (B) the person, or an affiliate of the person, during the 180-day period beginning on the date that is 90 days before the date on which the person files the petition described in subparagraph (A), engages in a short sale of any publicly traded security of the owner of the patent that is the subject of the petition. .